Drugs / SGB-7342
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07324850 | Jan → Oct 2026 expected | obesity disorder | Suzhou Sanegene Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGB-7342 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07324850 ↗ |
| Route | Subcutaneous | “subcutaneously administered SGB-7342” NCT07324850 ↗ |